title: Lactate dehydrogenase and body mass index are prognostic factors in patients with recurrent small cell lung cancer receiving amrubicin.
abstract: OBJECTIVE
  Amrubicin monotherapy can be an effective treatment option for patients with recurrent small cell lung cancer (SCLC). We conducted this retrospective study to investigate the prognostic factors in patients with recurrent SCLC receiving amrubicin monotherapy.
  
  
  METHODS
  The associations between survival and clinical data, including the performance status, body mass index (BMI), plasma lactate dehydrogenase (LDH) level, and plasma neuron-specific enolase level, were evaluated in patients with recurrent SCLC, and a subset analysis of patients with platinum-resistant disease was conducted.
  
  
  RESULTS
  In all, 37 patients were evaluated. The median survival from the date of initiation of amrubicin monotherapy was 9.1 months (95% confidence interval 4.7-12.0 months). Multivariate analysis using a Cox proportional hazard model identified the plasma LDH level (p = 0.049), BMI (p = 0.031), and platinum resistance (p = 0.032) as independent factors associated with survival. The same associations were also observed in the subset of patients with platinum-resistant disease.
  
  
  CONCLUSIONS
  Our findings suggest that the plasma LDH level and BMI may be useful prognostic factors in patients with SCLC receiving amrubicin monotherapy, including patients with platinum-resistant disease.
authors.affiliation: First Department of Internal Medicine, University of Toyama, Toyama City - Japan.
authors.forename: Minehiko
authors.initials: M
authors.lastname: Inomata
authors.affiliation: First Department of Internal Medicine, University of Toyama, Toyama City - Japan.
authors.forename: Ryuji
authors.initials: R
authors.lastname: Hayashi
authors.affiliation: First Department of Internal Medicine, University of Toyama, Toyama City - Japan.
authors.forename: Kotaro
authors.initials: K
authors.lastname: Tokui
authors.affiliation: First Department of Internal Medicine, University of Toyama, Toyama City - Japan.
authors.forename: Chihiro
authors.initials: C
authors.lastname: Taka
authors.affiliation: First Department of Internal Medicine, University of Toyama, Toyama City - Japan.
authors.forename: Seisuke
authors.initials: S
authors.lastname: Okazawa
authors.affiliation: First Department of Internal Medicine, University of Toyama, Toyama City - Japan.
authors.forename: Kenta
authors.initials: K
authors.lastname: Kambara
authors.affiliation: First Department of Internal Medicine, University of Toyama, Toyama City - Japan.
authors.forename: Tomomi
authors.initials: T
authors.lastname: Ichikawa
authors.affiliation: First Department of Internal Medicine, University of Toyama, Toyama City - Japan.
authors.forename: Toru
authors.initials: T
authors.lastname: Yamada
authors.affiliation: First Department of Internal Medicine, University of Toyama, Toyama City - Japan.
authors.forename: Toshiro
authors.initials: T
authors.lastname: Miwa
authors.affiliation: Department of Medical Oncology, Toyama University Hospital, Toyama City - Japan.
authors.forename: Tatsuhiko
authors.initials: T
authors.lastname: Kashii
authors.affiliation: First Department of Internal Medicine, University of Toyama, Toyama City - Japan.
authors.forename: Shoko
authors.initials: S
authors.lastname: Matsui
authors.affiliation: First Department of Internal Medicine, University of Toyama, Toyama City - Japan.
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Tobe
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018943:Anthracyclines / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D015415:Biomarkers; D015992:Body Mass Index; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D007770:L-Lactate Dehydrogenase / Q000097:blood*; D008175:Lung Neoplasms / Q000188:drug therapy / Q000453:epidemiology* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011379:Prognosis; D055752:Small Cell Lung Carcinoma / Q000188:drug therapy / Q000453:epidemiology* / Q000401:mortality / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D018943:Anthracyclines; D000970:Antineoplastic Agents; D015415:Biomarkers; C055866:amrubicin; D007770:L-Lactate Dehydrogenase